The Oslo University Hospital | Therakos Institute Courses

The Oslo University Hospital covers a complete spectrum of activities, from clinical research to patient care. In 2002, the hospital was transferred from county to state ownership and is now funded by government-owned trusts. More recently, the hospital merged with four other care units, strengthening its role as a local hospital and establishing more comprehensive pathways of patient care, and from June 2017 the Oslo University Hospital is a Comprehensive Cancer Center.

Annually, the hospital serves over 1 million patients across 40 different locations, and employs a staff of over 18,000. Among its several specialisations, the hospital caters for those in need of transplants and offers both procedures and after-care treatments. Research forms a large part of the offering, with the hospital being among the most active in all of Norway.

Upcoming Courses

Mar 25 - 26, 2025

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

The Oslo University Hospital, Oslo, Norway

Find out more

Oct 27 - 28, 2025

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

The Oslo University Hospital, Oslo, Norway

Find out more

Faculty

Alba Pons

Alba Pons has been working as a hematology nurse at the Oslo University Hospital since 2015. She has been involved in the ECP treatment since 2016, working with both adult and pediatric population, and became the ECP coordinator in 2021. She has also been involved in the development of internal procedures regarding ECP. Among his qualifications, she specializes in clinical nursing and fulfilled the Oslo University Hospital Clinical Competence Program in 2019.

Explore related courses

Mar 25 - 26, 2025

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

The Oslo University Hospital, Oslo, Norway

Find out more

Oct 27 - 28, 2025

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

The Oslo University Hospital, Oslo, Norway

Find out more

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

The Oslo University Hospital, Oslo, Norway

Upcoming Courses

Treating Patients with ECP from A–Z – The Nordic ApproachAdvancing Knowledge on ECP Technology

Treating Patients with ECP from A–Z – The Nordic ApproachAdvancing Knowledge on ECP Technology

Faculty

Alba Pons

Explore related courses

Treating Patients with ECP from A–Z – The Nordic ApproachAdvancing Knowledge on ECP Technology

Treating Patients with ECP from A–Z – The Nordic ApproachAdvancing Knowledge on ECP Technology

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

Treating Patients with ECP from A–Z – The Nordic Approach
Advancing Knowledge on ECP Technology

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS